Retension Pharmaceuticals (RTSN) closed at $11.36 on October 30, 2026, down 4.0% from the previous close, on volume of 58,693 shares (30-day average 159,238).
Data as of October 30, 2026.
No press releases found.
Catalyst watch: Election drama, jobs report, Apple and McDonald's in the earnings confessional
Seeking Alpha News (Fri, 30-Oct 3:00 PM ET)
Retension Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure.
Retension Pharmaceuticals trades on the NASDAQ stock market under the symbol RTSN.
As of October 30, 2026, RTSN stock price declined to $11.36 with 58,693 million shares trading.
RTSN has a market cap of $94.65 million. This is considered a Micro Cap stock.
RTSN support price is $10.71 and resistance is $12.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RTSN shares will trade within this expected range on the day.
